Gabriel S E
Department of Health Sciences Research, Mayo Foundation, Rochester, MN 55905, USA.
Ann Rheum Dis. 2008 Dec;67 Suppl 3(Suppl 3):iii30-4. doi: 10.1136/ard.2008.098038.
Premature death has been long recognised as a manifestation of rheumatoid arthritis (RA). Three lines of evidence can explain why patients with RA die prematurely and why the mortality gap between patients with RA and the general population appears to widening. First, patients with RA have a higher risk of several serious comorbid conditions and they tend to experience worse outcomes after the occurrence of these illnesses. Second, patients with RA do not appear to receive optimal primary or secondary preventive care. And third, the systemic inflammation and immune dysfunction associated with RA appears to promote and accelerate comorbidity and mortality. This paper provides a brief summary and interpretation of the data underlying these findings. Together, these results provide a compelling argument in favour of a focused research programme aimed specifically at eliminating premature death in patients with RA.
早死一直被公认为类风湿关节炎(RA)的一种表现形式。有三条证据可以解释为什么RA患者会过早死亡,以及为什么RA患者与普通人群之间的死亡率差距似乎在扩大。首先,RA患者患几种严重合并症的风险更高,而且在这些疾病发生后,他们往往会经历更糟糕的结局。其次,RA患者似乎没有得到最佳的一级或二级预防护理。第三,与RA相关的全身炎症和免疫功能障碍似乎会促进和加速合并症及死亡。本文对这些发现背后的数据进行了简要总结和解读。这些结果共同提供了一个令人信服的论据,支持开展一项专门针对消除RA患者过早死亡的重点研究项目。